BriaCell
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bellevue Ctr, 235 15th St Suite 300, Van...Phone Number
(604) 921-1810Website
www.briacell.comRevenue
-Stock Symbol
BCTXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About BriaCell
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Explore more
BriaCell Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BriaCell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BriaCell has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BriaCell has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
BriaCell, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if BriaCell had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at BriaCell
Check out if BriaCell is spiking on competitors!
Product Launch: Get notified when BriaCell launches new products
Earning: See what the market has to say on BriaCell recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined BriaCell as Masked Content
Find more new buyers
Compare Similar Companies to BriaCell
Compare insights from companies similar to BriaCell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BriaCell is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BriaCell is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BriaCell.
BriaCell financials insights
Gather financial insights about BriaCell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$265K
2021
Stock Offering
$59.5M
2023
Share Placement
$4M
2024
Share Placement
$5M
BriaCell Tech Stack
A closer look at the technologies used by BriaCell
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Pharmaceuticals
Left Company
Executive Move
Executive Moves, Left Company
Project
Product Management, Intellectual Property, Legal Affairs, Laboratory Operations, Clinical Operations, Healthcare Technology
Project
Laboratory Operations, Medical Research, Clinical Operations
BriaCell News & Media
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCBriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a key genetic engineering milestone, advancing the program toward clinical development.BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluaBriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inh
Read more news
Top Business Services Companies
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding BriaCell
Sign Up For FreeTo access detailed company insights
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for b... Read More
